Çalışmayı yürüten Mount SinaiIcahn Tıp Fakültesi Onkoloji Servisi Bölüm Direktörü Prof. Dr. Guy Montgomery, şu bilgileri verdi: “Bu sonuçlar, meme kanseri için radyoterapi alan hastalarda halsizliği kontrol altına almak için kanıta dayalı bir tamamlayıcı girişim olarak KDTH’ı desteklemektedir. KDTH, başka tedavi seçenekleri daha az olan hastaların halsizliğini azaltmada ve yaşam kalitesini arttırmakta işe yaramaktadır. Ayrıca invazif değil, advers yan etkiye sahip değil ve faydalı etkisi son girişimden uzun bir süre sonra da faydalı etkisi sürmektedir.”
Meme kanseri neden olur? Belirtileri, tedavisi ve elle muayenesi
İlave olarak, hastalar ayrıca KDTH’ye katılmanın rahatlatıcı ve yardımcı olduğunu bildirdiler. Prof. Dr. Montgomery, “Bu çalışma önemlidir, çünkü külfetli ve zor meme kanseri radyoterapi kürleri süresince ve uzun bir süre sonrasında da hastaların yaşam kalitesini iyileştirmeye yardımcı olan yeni bir girişim göstermektedir.” dedi.
Matalenin tam metnine aşağıdaki linkten ulaşılabilmektedir:
Abstract
Purpose: The objective of this study was to test the efficacy of cognitive-behavioral therapy plus hypnosis (CBTH) to control fatigue in patients with breast cancer undergoing radiotherapy. We hypothesized that patients in the CBTH group receiving radiotherapy would have lower levels of fatigue than patients in an attention control group.
Patients and Methods: Patients (n = 200) were randomly assigned to either the CBTH (n = 100; mean age, 55.59 years) or attention control (n = 100; mean age, 55.97 years) group. Fatigue was measured at four time points (baseline, end of radiotherapy, 4 weeks, and 6 months after radiotherapy). Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT) –Fatigue subscale and Visual Analog Scales (VASs; Fatigue and Muscle Weakness).
Results: The CBTH group had significantly lower levels of fatigue (FACIT) at the end of radiotherapy (z, 6.73; P < .001), 4-week follow-up (z, 6.98; P < .001), and 6-month follow-up (z, 7.99; P < .001) assessments. Fatigue VAS scores were significantly lower in the CBTH group at the end of treatment (z, 5.81; P < .001) and at the 6-month follow-up (z, 4.56; P < .001), but not at the 4-week follow-up (P < .07). Muscle Weakness VAS scores were significantly lower in the CBTH group at the end of treatment (z, 9.30; P < .001) and at the 6-month follow-up (z, 3.10; P < .02), but not at the 4-week follow-up (P < .13).
Conclusion: The results support CBTH as an evidence-based intervention to control fatigue in patients undergoing radiotherapy for breast cancer. CBTH is noninvasive, has no adverse effects, and its beneficial effects persist long after the last intervention session. CBTH seems to be a candidate for future dissemination and implementation.
YAZIYI PAYLAŞ
YORUMUNUZ VAR MI?